Cobra venom factor: Structure, function, and humanization for therapeutic complement depletion

被引：124

作者：

Vogel, Carl-Wilhelm ^{[1
]}

Fritzinger, David C. ^{[1
]}

机构：

[1] Univ Hawaii Manoa, Canc Res Ctr Hawaii, Honolulu, HI 96813 USA

来源：

TOXICON | 2010年 / 56卷 / 07期

关键词：

Complement; C3; Cobra venom factor; CVF; Convertase; Protein humanization; Therapeutic complement depletion; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; CARBOXYPEPTIDASE-N-DEFICIENCY; ISCHEMIA-REPERFUSION INJURY; FACTOR HYBRID PROTEINS; HUMAN C3 DERIVATIVES; ALTERNATIVE PATHWAY; NAJA-NAJA; FACTOR-B; 3RD COMPONENT; MACULAR DEGENERATION;

D O I：

10.1016/j.toxicon.2010.04.007

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Cobra venom factor (CVF) is the complement-activating protein in cobra venom. This manuscript reviews the structure and function of CVF, how it interacts with the complement system, the structural and functional homology to complement component C3, and the use of CVF as an experimental tool to decomplement laboratory animals to study the functions of complement in host defense and immune response as well as in the pathogenesis of diseases. This manuscript also reviews the recent progress in using the homology between CVF and C3 to study C3 structure and function, and to develop human C3 derivatives with the complement-depleting function of CVF. These human C3 derivatives represent humanized CVF, and are a conceptually different concept for pharmacological intervention of the complement system, therapeutic complement depletion. The use of humanized CVF for therapeutic complement depletion in several pre-clinical models of human diseases is also reviewed. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：1198 / 1222

页数：25

共 173 条

[1] COBRA VENOM FACTOR - EVIDENCE FOR ITS BEING ALTERED COBRA C3 (3RD COMPONENT OF COMPLEMENT) [J].

ALPER, CA ;

BALAVITCH, D .

SCIENCE, 1976, 191 (4233) :1275-1276

[2] PHYLOGENY OF THE 3RD COMPONENT OF COMPLEMENT, C3 - ANALYSIS OF THE CONSERVATION OF HUMAN-CR-1, HUMAN-CR-2, HUMAN-H, AND HUMAN-B SITES, CONCANAVALIN-A BINDING-SITES, AND THIOLESTER BOND IN THE C3 FROM DIFFERENT SPECIES [J].

ALSENZ, J ;

AVILA, D ;

HUEMER, HP ;

ESPARZA, I ;

BECHERER, JD ;

KINOSHITA, T ;

WANG, Y ;

OPPERMANN, S ;

LAMBRIS, JD .

DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY, 1992, 16 (01) :63-76

[3] Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma [J].

Anderson, DR ;

GrilloLopez, A ;

Varns, C ;

Chambers, KS ;

Hanna, N .

BIOCHEMICAL SOCIETY TRANSACTIONS, 1997, 25 (02) :705-708

[4] Generation and characterization of transgenic mice expressing cobra venom factor [J].

Andrä, J ;

Halter, R ;

Kock, MA ;

Niemann, H ;

Vogel, CW ;

Paul, D .

MOLECULAR IMMUNOLOGY, 2002, 39 (5-6) :357-365

[5] PLASMA COMPLEMENT CHANGES DURING BRONCHOSPASM PROVOKED IN ASTHMATIC-PATIENTS [J].

ARROYAVE, CM ;

STEVENSON, DD ;

VAUGHAN, JH ;

TAN, EM .

CLINICAL ALLERGY, 1977, 7 (02) :173-182

[6] The role of the complement system in ischemia-reperfusion injury [J].

Arumugam, TV ;

Shiels, IA ;

Woodruff, TM ;

Granger, DN ;

Taylor, SM .

SHOCK, 2004, 21 (05) :401-409

[7] cDNA cloning and expression of cobrin, the C3-cleaving metalloprotease from cobra venom [J].

Bambai, B ;

Teppke, M ;

Bredehorst, R ;

Vogel, CW .

MOLECULAR IMMUNOLOGY, 1998, 35 (6-7) :408-408

[8]

Bammert H., 2002, INT IMMUNOPHARMACOL, V2, P1275

[9] Targeted Inhibition of the Complement Alternative Pathway with Complement Receptor 2 and Factor H Attenuates Collagen Antibody-Induced Arthritis in Mice [J].

Banda, Nirmal K. ;

Levitt, Brandt ;

Glogowska, Magdalena J. ;

Thurman, Joshua M. ;

Takahashi, Kazue ;

Stahl, Gregory L. ;

Tomlinson, Stephen ;

Arend, William P. ;

Holers, V. Michael .

JOURNAL OF IMMUNOLOGY, 2009, 183 (09) :5928-5937

[10]

BAUMAN N, 1978, J IMMUNOL, V120, P1763

← 1 2 3 4 5 6 7 8 9 10 →